T1	p 325 370	of 95 patients with atherosclerotic disease .
T2	i 27 31	acid
T3	i 58 70	lipid esters
T4	i 78 92	lipid-lowering
T5	i 108 142	diet , clofibrate and niceritrol .
T6	i 187 197	clofibrate
T7	i 263 275	lipid esters
T8	i 478 529	clofibrate or niceritrol , a nicotinic acid ester ,
T9	i 632 641	treatment
T10	i 647 679	diet , clofibrate and niceritrol
T11	i 778 784	esters
T12	i 928 979	saturated and monounsaturated fatty acids secreased
T13	i 988 1015	polyunsaturated fatty acids
T14	i 1268 1278	clofibrate
T15	i 1360 1370	Clofibrate
T16	i 1905 1915	clofibrate
T17	i 1961 1971	clofibrate
T18	i 2026 2046	polyunsaturated fats
T19	i 2080 2095	polyunsaturated
T20	i 2099 2126	monounsaturated fatty acids
T21	i 2147 2153	esters
T22	i 2236 2241	fatty
T23	i 2283 2293	clofibrate
T24	i 2347 2362	polyunsaturated
T25	o 21 43	fatty acid composition
T26	o 160 183	proportion of linoleate
T27	o 187 197	clofibrate
T28	o 226 248	fatty acid composition
T29	o 256 268	plasma lipid
T30	o 706 757	serum lipid reductions . The fatty acid composition
T31	o 765 784	plasma lipid esters
T32	o 849 878	degree of dietary adherence .
T33	o 1335 1380	fatty acid composition . Clofibrate treatment
T34	o 1486 1524	cholesterol esters , triglycerides and
T35	o 1586 1605	content of linoleic
T36	o 1613 1621	2 ) acid
T37	o 1634 1672	cholesterol esters and triglycerides .
T38	o 1689 1696	1 ratio
T39	o 1770 1779	P/S ratio
T40	o 2344 2366	of polyunsaturated fat